Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TAK-079 in Combination With Standard Background Therapy in Patients With Moderate to Severe Systemic Lupus Erythematosus

Trial Profile

A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TAK-079 in Combination With Standard Background Therapy in Patients With Moderate to Severe Systemic Lupus Erythematosus

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TAK 079 (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 01 Mar 2019 According to a Lupus Therapeutics media release, the company alongwith its affiliate The Lupus Research Alliance entered into a collaboration with Takeda Pharmaceutical Company for this trial. The study will be conducted in 20 research centers throughout the U.S., many of which are members of Lupus Therapeutics' Lupus Clinical Investigators Network (LuCIN).
    • 06 Dec 2018 Status changed from not yet recruiting to recruiting.
    • 02 Nov 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top